Homozygous Familial Hypercholesterolemia (HoFH) Market to Observe Stupendous Growth During the Forecast Period (2022-2032) - DelveInsight | Key Companies - Aegerion, Akeso, Alnylam Pharma, Amgen, Arrowhead Pharma, Innovent Biologics, LIB Therapeutics, Neu

As per DelveInsight, the Homozygous Familial Hypercholesterolemia Market is expected to grow in the coming years owing to the rise in the number of prevalent cases, the improvement in the research and development activities, and the launch of emerging therapies.

The pipeline of Homozygous Familial Hypercholesterolemia (HoFH) possess few potential key players, such as Regeneron Pharmaceuticals, Novartis, LIB Therapeutics and NeuroBo Pharmaceuticals. However, the emerging therapies hold immense potential to transform the treatment scenario and market outlook.

DelveInsight's "Homozygous Familial Hypercholesterolemia (HoFH) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Homozygous Familial Hypercholesterolemia Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Homozygous Familial Hypercholesterolemia market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Homozygous Familial Hypercholesterolemia (HoFH): An Overview
Familial hypercholesterolaemia (FH) is an inherited disease leading to a very high serum cholesterol, present from birth, due to mutations affecting low density lipoprotein receptor (LDLR) activity. Most commonly, individuals have heterozygous familial hypercholesterolemia (HeFH), caused by a single DNA variant (alteration) for FH that they have inherited from one (affected) parent. In rare cases, an individual can have homozygous familial hypercholesterolemia (HoFH), caused by having two causal FH DNA variants, where one variant is inherited from each (affected) parent. Individuals with HoFH typically have a more severe form of disease.

Individuals with HoFH exhibit extremely high levels of low-density lipoprotein cholesterol (LDL-C), usually above 400 mg/dL. They usually have xanthomas (firm nodules caused by cholesterol buildup as a result of the very high levels of LDL-C) by early childhood. Planar xanthomas affecting the skin on the hands, elbows, buttocks and knees in a young patients are considered as the diagnostic symptom for this condition. Corneal arcus surrounding the entire inside edge of the cornea is often present.

Homozygous Familial Hypercholesterolemia Market Key Facts
• As per a study conducted by Sánchez-Hernández et al., (2016) titled "Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship", a total of 97 subjects were identified as having HoFH-of whom, 47 were true homozygous (1 for APOB, 5 for LDLRAP1, and 41 for LDLR), 45 compound heterozygous for LDLR, 3 double heterozygous for LDLR and PSCK9, and 2 double heterozygous for LDLR and APOB. No PSCK9 homozygous cases were identified. Two variants in LDLR were identified in 4.8% of the molecular studies.
• Vallejo-Va et al. (2018) conducted a study titled "Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)" and reported that in Germany an estimated prevalence of FH is about 1:300 (HoFH: 1:860,000), which suggests that approximately 275,000 individuals may have FH, but only a minority are diagnosed/treated.
• The prevalence of HoFH is markedly increased in certain regions of the world, and may be as high as one in thirty thousand in some populations.
• Patients with HoFH are often diagnosed early in childhood, do not respond well to medical therapy, and can progress rapidly to premature coronary artery disease.

Homozygous Familial Hypercholesterolemia Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Homozygous Familial Hypercholesterolemia market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Homozygous Familial Hypercholesterolemia market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Homozygous Familial Hypercholesterolemia Market will Grow by 2032:
https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Homozygous Familial Hypercholesterolemia Epidemiology
The epidemiology section covers detailed insights into the historical and current Homozygous Familial Hypercholesterolemia patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Epidemiology Segmented as -
• Prevalent Population of Familial Hypercholesterolemia (FH) in the 7MM [2019-2032]
• Diagnosed and Treatable Cases of Homozygous Familial Hypercholesterolemia in the 7MM [2019-2032]
• Prevalent Population of Homozygous Familial Hypercholesterolemia in the 7MM [2019-2032]

Get Key Insights Into the Evolving Homozygous Familial Hypercholesterolemia Epidemiology Trends:
https://www.delveinsight.com/report-store/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Homozygous Familial Hypercholesterolemia Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Homozygous Familial Hypercholesterolemia market or expected to be launched during the study period. The analysis covers Homozygous Familial Hypercholesterolemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Homozygous Familial Hypercholesterolemia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Homozygous Familial Hypercholesterolemia Therapeutics Assessment
The pipeline for Homozygous Familial Hypercholesterolemia (HoFH) is not quite robust, with few emerging drugs in the pipeline. With increasing research and development, there might be an increase in new therapies focused on curing HoFH. This will uplift the market in the forecast period of 2020-2030.

Currently, only a few companies are developing therapies for Homozygous Familial Hypercholesterolemia. Currently, Arrowhead Pharmaceuticals is leading the therapeutics market with its Homozygous Familial Hypercholesterolemia drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Homozygous Familial Hypercholesterolemia Therapeutics Market Include:
• Aegerion Pharmaceutical
• Akeso Biopharma
• Alnylam Pharmaceuticals
• Amgen
• Arrowhead Pharmaceuticals
• Innovent Biologics
• LIB Therapeutics LLC
• Neurobo Pharmaceuticals
• Novartis Pharmaceuticals
• Regeneron
• Regeneron Pharmaceuticals
• Sanofi
• Verve Therapeutics
And Many Others

Homozygous Familial Hypercholesterolemia Emerging and Marketed Drugs Covered in the Report Include:
• ANGPTL3 Program: Verve Therapeutics
• ARO-ANG 3: Arrowhead Pharmaceuticals
• Ebronucimab: Akeso Biopharma
• Evinacumab: Regeneron
• Gemcabene: NeuroBo Pharmaceuticals
• Inclisiran: Novartis Pharmaceuticals
• LIB003: LIB Therapeutics
• Praluent: Regeneron
• Tafolecimab: Innovent Biologics
• Juxtapid (lomitapide): Aegerion Pharmaceuticals
• Repatha (evolocumab): Amgen
And Many More

Learn More About the Emerging Therapies & Key Companies in the Homozygous Familial Hypercholesterolemia Therapeutics Market:
https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Homozygous Familial Hypercholesterolemia Competitive Intelligence Analysis
4. Homozygous Familial Hypercholesterolemia Market Overview at a Glance
5. Homozygous Familial Hypercholesterolemia Background and Overview
6. Homozygous Familial Hypercholesterolemia Patient Journey
7. Homozygous Familial Hypercholesterolemia Epidemiology and Patient Population
8. Homozygous Familial Hypercholesterolemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Homozygous Familial Hypercholesterolemia Unmet Needs
10. Key Endpoints of Homozygous Familial Hypercholesterolemia Treatment
11. Homozygous Familial Hypercholesterolemia Marketed Products
12. Homozygous Familial Hypercholesterolemia Emerging Therapies
13. Homozygous Familial Hypercholesterolemia Seven Major Market Analysis
14. Attribute Analysis
15. Homozygous Familial Hypercholesterolemia Market Outlook (7 major markets)
16. Homozygous Familial Hypercholesterolemia Access and Reimbursement Overview
17. KOL Views on the Homozygous Familial Hypercholesterolemia Market.
18. Homozygous Familial Hypercholesterolemia Market Drivers
19. Homozygous Familial Hypercholesterolemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/homozygous-familial-hypercholesterolemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.